Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:29am CET

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

 
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; [email protected]

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
01/19 MERCK AND : These Two Biotechs Just Reported Key Data
01/19 EISAI : and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA®..
01/19 MERCK AND : First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patie..
01/19 MERCK AND : LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of..
01/19 MERCK AND : chalks up another win for Keytruda in lung cancer
01/18 MERCK AND : shares continue to rise after successful lung cancer trial
01/18 MERCK AND : The Consumer Health of Merck Walks the Talk with its WE100 Movement
01/17 MERCK AND : KEYTRUDA Significantly Improved Overall Survival and Progression-Fre..
01/17 MERCK AND : Keytruda aces another lung cancer study
01/17 MERCK AND COMPANY : Today’s Research Reports on Stocks to Watch: Bristol-Myers S..
More news
News from SeekingAlpha
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 Merck's Keytruda shows treatment effect in mid-stage liver cancer study
01/19 AstraZeneca's Lynparza OK'd in Japan for ovarian cancer; shares up 1% premark..
01/18 Big Biopharma in the red in early trade
01/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 17, 2018
Financials ($)
Sales 2017 40 228 M
EBIT 2017 13 722 M
Net income 2017 5 361 M
Debt 2017 13 116 M
Yield 2017 3,08%
P/E ratio 2017 30,03
P/E ratio 2018 19,72
EV / Sales 2017 4,48x
EV / Sales 2018 4,35x
Capitalization 167 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 66,9 $
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.24%167 132
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
AMGEN8.11%137 400